+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015

  • ID: 3422669
  • Report
  • August 2015
  • 104 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akron Molecules AG
  • AstraZeneca Plc
  • Bayer AG
  • Celon Pharma Sp. z o.o.
  • Pfizer Inc.
  • Sareum Holdings Plc
  • MORE
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015

Summary

The report ‘Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015’, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Anaplastic Large Cell Lymphoma (ALCL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Anaplastic Large Cell Lymphoma (ALCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Large Cell Lymphoma (ALCL) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • Akron Molecules AG
  • AstraZeneca Plc
  • Bayer AG
  • Celon Pharma Sp. z o.o.
  • Pfizer Inc.
  • Sareum Holdings Plc
  • MORE
List of Tables

List of Figures

Introduction

REPORT COVERAGE

Anaplastic Large Cell Lymphoma (ALCL) Overview

Therapeutics Development

Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview

Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis

Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies

Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Investigation by Universities/Institutes

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies

Anaplastic Large Cell Lymphoma (ALCL) - Products under Investigation by Universities/Institutes

Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development

Akron Molecules AG

AstraZeneca Plc

Bayer AG

Celon Pharma Sp. z o.o.

Pfizer Inc.

Sareum Holdings Plc

Seattle Genetics, Inc.

Teva Pharmaceutical Industries Limited

Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AdIL-24 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AKR-302 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AKR-303 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AZD-3463 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brentuximab vedotin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CEP-28122 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CEP-37440 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

copanlisib hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

crizotinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KRA-0008 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SH-7129 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Anaplastic Large Cell Lymphoma (ALCL) - Recent Pipeline Updates

Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects

Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products

Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones

Featured News & Press Releases

Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting

Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting

Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014

Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting

Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress

Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion", Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan

Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma

Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma

Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2015

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Akron Molecules AG, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca Plc, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings Plc, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Recent Pipeline Updates, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2015

Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
4 of 5
Akron Molecules AG
AstraZeneca Plc
Bayer AG
Celon Pharma Sp. z o.o.
Pfizer Inc.
Sareum Holdings Plc
Seattle Genetics, Inc.
Teva Pharmaceutical Industries Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll